[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488450":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":39,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":25,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":25,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of Chicago","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Early Tocilizumab","EXPERIMENTAL","This arm will receive tocilizumab 80 mg at the time of acute chest syndrome diagnosis and subsequent randomization. Then, two days later, they will receive 50 mL of normal saline.",[13],"Drug: Tocilizumab",{"label":15,"type":16,"description":17,"interventionNames":18},"Delayed Tocilizumab","ACTIVE_COMPARATOR","This arm will receive 50 mL of normal saline at the time of acute chest syndrome diagnosis and subsequent randomization. Then, two days later, they will receive tocilizumab 80 mg. Thus, this delayed arm will serve as a placebo comparator for the first 48 hours and then as an active comparator for the remaining duration on study.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tocilizumab","Tocilizumab 80 mg IV dose (one time per patient)",[15,9],null,[27],{"name":28,"affiliation":5,"role":29},"Austin Wesevich, MD","PRINCIPAL_INVESTIGATOR",[31,35],{"name":28,"role":32,"phone":33,"phoneExt":25,"email":34},"CONTACT","773-834-6732","austin.wesevich@uchicagomedicine.org",{"name":36,"role":32,"phone":37,"phoneExt":25,"email":38},"Gabrielle Lapping-Carr, MD","773-702-6808","glappingcarr@uchicago.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Chicago","Illinois","60637","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-87.65005,41.85003,{"lat":51,"lon":50},[54],{"name":28,"role":32,"phone":33,"phoneExt":25,"email":34},{"type":56,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100488450","phase-2-tocilizumab-for-acute-chest-syndrome-100488450",false,"NCT05640271","Tocilizumab for Acute Chest Syndrome","Low-Dose Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease","Inclusion Criteria:\n\n* Adults ≥ 12 years of age\n* Prior diagnosis of sickle cell disease (Hb SS, Hb SC, Hb Sb+, and Hb Sb0)\n\nExclusion Criteria:\n\n* Pregnant patients or breastfeeding mothers.\n* Prior treatment with gene therapy or a stem cell transplant.\n* Current enrollment in a clinical trial involving an FDA-regulated drug or biologic.\n* Current neutropenia (absolute neutrophil count \\< 1000\u002Fmm\\^3)\n* Current thrombocytopenia (platelet count \\< 50,000 mm\\^3)\n* Aspartate aminotransferase (AST) or alanine transaminase (ALT) \\> 10 times the upper limit of normal (ULN)\n* History of tuberculosis (TB).\n* Positive purified protein derivative (PPD) TB screening test.\n* On active therapy with a Bruton's tyrosine kinase-targeted agent, which include the following: Acalabrutinib, Ibrutinib, Zanubrutinib\n* On active therapy with a JAK2-targeted agent, which include the following: Baricitinib, Ruxolitinib, Tofacitinib, Upadacitinib\n* Any of the following biologic immunosuppressive agent (and any biosimilar versions thereof) administered in the past 6 months:\n\nAbatacept, Adalimumab, Alemtuzumab, Atezolizumab, Belimumab, Blinatumomab, Brentuximab, Certolizumab, Daratumumab, Durvalumab, Eculizumab, Elotuzumab, Etanercept, Gemtuzumab, Golimumab, Ibritumomab, Infliximab, Inotuzumab, Ipilimumab, Ixekizumab, Moxetumomab, Nivolumab, Obinutuzumab, Ocrelizumab, Ofatumumab, Pembrolizumab, Polatuzumab, Rituximab, Sarilumab, Secukinumab, Tocilizumab, Tositumumab, Tremelimumab, Urelumab, Ustekinumab","ALL","12 Years",{"count":67,"type":68},200,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease. Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with chimeric antigen receptor T-cell (CAR-T) therapy, and it is also authorized for treatment of COVID-19. Since IL-6 levels are elevated in the sputum of patients with acute chest syndrome, the investigators are hopeful that this will be an effective strategy. The investigators will be looking at how a low dose of tocilizumab affects oxygen status, clinical outcomes, and laboratory markers in patients admitted to the hospital with acute chest syndrome.",[74,75],"Sickle Cell Disease","Acute Chest Syndrome","2026-03-31",{"date":78,"type":79},"2026-04-06","ACTUAL",{"date":81,"type":79},"2023-04-10",{"date":83,"type":68},"2027-01",{"name":5,"class":6},1]